Anti-LRP4 Antibody [N207/27 (Formerly sold as S207-27)]

(No reviews yet) Write a Review
SKU:
STMA00128
Antibody Type:
Recombinant Monoclonal
Applications:
WB
Applications:
ICC/IF
Reactivity:
Human
Reactivity:
Mouse
Reactivity:
Rat
Host Species:
Mouse
Isotype:
IgG2A
  • Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-LRP4 (Extracellular) Monoclonal Antibody, Clone N207/27 (STMA00128). Tissue: Neuroblastoma cells (SH-SY5Y). Species: Human. Fixation: 4% PFA for 15 min. Primary Antibody: Mouse Anti-LRP4 (Extracellular) Monoclonal Antibody (STMA00128) at 1:200 for overnight at 4°C with slow rocking. Secondary Antibody: AlexaFluor 488 at 1:1000 for 1 hour at RT.
  • Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-LRP4 Monoclonal Antibody, Clone N207/27 (STMA00128). Tissue: COS cells transfected with 2 ug human LRP4 plasmid. Species: Human. Fixation: 4% PFA for 10 min. Primary Antibody: Mouse Anti-LRP4 Monoclonal Antibody (STMA00128) at 1:100 for 1 hour at RT. Secondary Antibody: Goat anti-mouse: Alexa 488. Counterstain: DAPI.
  • Western Blot analysis of Rat brain membrane lysate showing detection of LRP4 protein using Mouse Anti-LRP4 Monoclonal Antibody, Clone N207/27 (STMA00128). Primary Antibody: Mouse Anti-LRP4 Monoclonal Antibody (STMA00128) at 1:500, 1:1000, and 1:2000.
Frequently bought together:

Description

LRP4 Antibody [N207/27 (Formerly sold as S207-27)]

LRP4 Antibody [N207/27 (Formerly sold as S207-27)] is a mouse recombinant monoclonal antibody directed against LRP4, offered by Assay Genie for research applications. Reported applications include WB and ICC/IF. Reported reactivity: Human, Mouse and Rat. Supplied as IgG2A, purified by Protein G.

LRP4 (Low-Density Lipoprotein Receptor-Related Protein 4) is a transmembrane receptor essential for neuromuscular junction formation and synaptic signaling. It acts as a co-receptor for agrin and MuSK, facilitating synapse development and maintenance. In the central nervous system, LRP4 influences astrocyte-neuron communication and synaptic plasticity. Mutations or autoantibodies targeting LRP4 are linked to myasthenia gravis and may contribute to cognitive dysfunction. Emerging evidence suggests LRP4 plays a role in neurodegenerative diseases by modulating synaptic integrity and glial function. Its involvement in both peripheral and central synaptic regulation positions LRP4 as a promising target for therapeutic intervention in neuromuscular and neurodegenerative disorders. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.

View AllClose

0 Reviews

View AllClose